Author

Thomas De Somer

ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING
ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING

ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING
ACCEPTANCE OF SWITCH, PATIENT SATISFACTION AND ADVERSE EVENTS AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR SB5 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A REAL-LIFE SETTING

Thomas De Somer  et al.

EVALUATION OF TROUGH LEVEL AND DISEASE ACTIVITY AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
EVALUATION OF TROUGH LEVEL AND DISEASE ACTIVITY AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Thomas De Somer  et al.

Item 1 - 3 / 3
1